Skip to main content
Equibles
ONMD logo

ONMD · OneMedNet Corp · Metrics

Track ONMD — free

Use ONMD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ONMD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.75 +0.13 (+2.77%) At close · Oct 20
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company has incurred recurring operating losses since its inception, including $2.3 million and $2.1 million for the three months ended June 30, 2026 and 2025, respectively. In addition, the Company had an accumulated deficit of $109.0 million as of June 30, 2026. The Company's cash balance of $0.4 million is not adequate to fund its operations through at least twelve months from the date these condensed consolidated financial statements were available for issuance. Therefore, these conditions raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$28.15M
Shares
5.93M
Volume · Oct 20 6757 Avg daily vol (16 sessions) 63.98K

ONMD metrics

71 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$4.75
Market cap
$28.15M

Price action

20 metrics
Price change (1W)
+18.1%
Price change (30D)
-8.9%
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
—
Annualized volatility (3M)
—
Beta
—
RSI (14D)
44.0
Price vs SMA 50
—
Price vs SMA 200
—
Avg volume (3M)
—
Relative volume
—
Average dollar volume
—

Company

3 metrics
Sector
Healthcare
Industry
Health Information Services
Shares outstanding
5.93M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
19.2×
reciprocal yield 5.2%
EV / EBITDA
—
EV / EBIT
—
P / sales
19.3×
reciprocal yield 5.2%
P / book
—
FCF yield
-24.5%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-30.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
47.8×
reciprocal yield 2.1%
EV / revenue historical average (5Y)
47.8×
reciprocal yield 2.1%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
-67.6%
Operating margin
-700.5%
Trailing 12 months
Net margin
-584.6%
Gross profit (TTM)
−$983,000
Operating profit (TTM)
−$10.19M
Net income (TTM)
−$8.51M
Trailing 12 months
Diluted EPS (TTM)
$-1.50
FCF margin
-473.7%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.27
Gross profit per diluted share (TTM)
$-0.17
Operating profit per diluted share (TTM)
$-1.87
EBITDA per diluted share (TTM)
$-1.87
Net income per diluted share (TTM)
$-1.55
Operating cash flow per diluted share (TTM)
$-1.26
Free cash flow per diluted share (TTM)
$-1.26
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
$0.26
Stock compensation per diluted share (TTM)
$0.47
Book value per share
$-0.57

Growth

11 metrics
Revenue growth YoY
+88.4%
Year over year
Net income growth YoY
-172.8%
Revenue (TTM)
$1.46M
Trailing 12 months
EPS growth YoY
-157.1%
Shares change YoY
+51.1%
Year over year · more shares
Revenue CAGR (3Y)
+5.6%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-623.6%
Debt / equity
—
Current ratio
0.3
EBITDA (TTM)
−$10.16M
Free cash flow (TTM)
−$6.89M
Quick ratio
0.3
Interest coverage
-308.9
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$226,000
Latest balance sheet
Cash & equivalents
$358,000
Total assets
$1.36M
Total debt
$132,000

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$6.88M
Capital expenditures (TTM)
$16,000
R&D (TTM)
$1.42M
SG&A (TTM)
—
Stock compensation (TTM)
$2.52M
R&D / revenue
97.6%
Stock compensation / revenue
173.3%

Ownership (13F)

9 metrics
13F filers
31
13F filer change QoQ
-2
Institutional ownership
25.1%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
0.3%
Private-fund adviser ownership
0.3%
Active holders' share change QoQ
+1,326.0%
Holder tenure
1.7
Price vs estimated holder cost
-15.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
2.5%

Short interest

3 metrics
Short interest
1.9%
Latest settlement · 1.2 days to cover
Days to cover
1.2d
Short-squeeze score
61 / 100

Insider activity

2 metrics
Net insider buying (90D)
$2.02M
Insider-sentiment score
87 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1849380 CUSIP 68270C202 13F (30d) 1 filings 1 filers Visit website Investor relations